睿知中国医院研究地图
候选清单

哈尔滨哈尔滨医科大学

哈尔滨医科大学附属第二医院

Second Affiliated Hospital of Harbin Medical University

在本站收录的 53 种疾病中,这家医院列在其中 16 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

哈尔滨医科大学附属第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma49 篇牵头论文
  2. 胃癌Stomach cancer35 篇牵头论文
  3. 骨肉瘤Osteosarcoma12 篇牵头论文
  4. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  5. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  6. 多发性骨髓瘤Multiple myeloma6 篇牵头论文
  7. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder1 篇牵头论文
  8. 重症肌无力Myasthenia gravis8 篇牵头论文
  9. 肝包虫病Hepatic echinococcosis0 篇牵头论文
  10. 特发性肺纤维化Idiopathic pulmonary fibrosis11 篇牵头论文
  11. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
  12. 法布雷病Fabry disease0 篇牵头论文
  13. 白塞病Behçet disease1 篇牵头论文
  14. IgA 肾病IgA nephropathy3 篇牵头论文
  15. 先天性膈疝Congenital diaphragmatic hernia0 篇牵头论文
  16. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 49 篇,占 0.3%。

牵头论文
49
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 6620222023: 141420232024: 151520242025: 882025

哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文49
  1. Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Exploring extrahepatic metastasis of hepatocellular carcinoma based on methylation driver genes and establishing a prognostic model for hepatocellular carcinoma.2025Gene
  4. SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma.2025Histology and histopathology
  5. Disulfidptosis-related genes RPN1 inhibits the progression of hepatocellular carcinoma by regulating cell cycle, may be a new therapeutic targets.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]免费全文
  6. Celecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levels.2025Journal of hazardous materials
  7. Exploring the mechanism of Naringenin in the treatment of hepatocellular carcinoma based on mRNA sequencing and experimental validation.2025Scientific reports免费全文
  8. Tumor-resident Malassezia can promote hepatocellular carcinoma development by downregulating bile acid synthesis and modulating tumor microenvironment.2025Scientific reports免费全文
  9. The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell death免费全文
  10. Peripheral T-cell subsets in radiofrequency ablation for tumors from different origins.2024Asian journal of surgery
  11. The Wnt signaling pathway in hepatocellular carcinoma: Regulatory mechanisms and therapeutic prospects.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  12. NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma.2024Cancer communications (London, England)免费全文
  13. Neutrophil extracellular traps promote immune escape in hepatocellular carcinoma by up-regulating CD73 through Notch2.2024Cancer letters
  14. ANGPTL4 Stabilizes Bone Morphogenetic Protein 7 Through Deubiquitination and Promotes HCC Proliferation via the SMAD/MAPK Pathway.2024DNA and cell biology
  15. Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis.2024DNA and cell biology
  16. Effect of Deletion of ANGPTL4 Gene on Viability, Migration and Invasion Ability and Apoptosis of Hepatocellular Carcinoma Cells.2024Discovery medicine
  17. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.2024Frontiers in immunology免费全文
  18. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.2024Frontiers in immunology免费全文
  19. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  20. Construction and validation of prognostic signature for transcription factors regulating T cell exhaustion in hepatocellular carcinoma.2024Medicine免费全文
  21. Tumor-Targeted CO Nanodelivery System Design and Therapy for Hepatocellular Carcinoma.2024Molecular pharmaceutics
  22. GABPA-Mediated Expression of HPN-AS1 Facilitates Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma by Promoting eIF4A3 Degradation.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  23. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  24. Efficacy and Interpretability Analysis of Noninvasive Imaging Based on Computed Tomography in Patients with Hepatocellular Carcinoma After Initial Transarterial Chemoembolization.2023Academic radiology
  25. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma.2023Academic radiology
  26. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.2023BMC cancer免费全文
  27. An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.2023Clinics and research in hepatology and gastroenterologyRCT
  28. Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma.2023Computers in biology and medicine
  29. Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion.2023Drug delivery免费全文
  30. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.2023European journal of radiology
  31. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC.2023Frontiers in immunology免费全文
  32. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  33. Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression.2023Hepatology international免费全文
  34. Clathrin light chain A-enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis.2023Journal of extracellular vesicles免费全文
  35. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.2023La Radiologia medica
  36. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.2023Pathology, research and practice
  37. Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.2023Radiology and oncologyRCT免费全文
  38. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.2022Analytical cellular pathology (Amsterdam)免费全文
  39. Reprogramming of central carbon metabolism in hepatocellular carcinoma.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  40. Targeting uridine-cytidine kinase 2 induced cell cycle arrest through dual mechanism and could improve the immune response of hepatocellular carcinoma.2022Cellular & molecular biology letters免费全文
  41. Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.2022Contrast media & molecular imaging免费全文
  42. The Role of ANGPTL Gene Family Members in Hepatocellular Carcinoma.2022Disease markers免费全文
  43. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  44. Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  45. The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  46. Preparation of Poly[lactic-co-glycolic] Acid Nanospheres and Its Role in Hepatoma Cells.2021Journal of nanoscience and nanotechnology
  47. Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  48. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis.2021Microvascular research
  49. Cyclin B1 acts as a tumor microenvironment-related cancer promoter and prognostic biomarker in hepatocellular carcinoma.2021The Journal of international medical research免费全文

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.4%。

牵头论文
35
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 8820222023: 5520232024: 7720242025: 992025

哈尔滨有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科眼科/神经眼科

这些论文过半是实验室或动物研究。

牵头的论文35
  1. Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.2026Ocular immunology and inflammation
  2. Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS).2025BMC medicineRCT免费全文
  3. Investigating the dysregulation of genes associated with glucose and lipid metabolism in gastric cancer and their influence on immunity and prognosis.2025BioFactors (Oxford, England)免费全文
  4. MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer.2025Biochimica et biophysica acta. Molecular basis of disease
  5. Gastric cancer-derived exosomal miR-196a-5p remodels the pre-metastatic niche for peritoneal dissemination.2025Cellular signalling
  6. Magnetic anchors with line-guided endoscopic full-thickness resection for gastric submucosal tumors.2025European journal of medical research免费全文
  7. Molecular Mechanisms of Neutrophil Extracellular Traps in Promoting Gastric Cancer Epithelial-Mesenchymal Transition Through SERPINE-1 Expression.2025Journal of biochemical and molecular toxicology免费全文
  8. Artificial Intelligence-Guided Identification of IGFBP7 as a Critical Indicator in Lactic Metabolism Determines Immunotherapy Response in Stomach Adenocarcinoma.2025Journal of cellular and molecular medicine免费全文
  9. Calcium overload via PVT1 reprograms neutrophil fate and constrains gastric cancer progression.2025Journal of translational medicine免费全文
  10. Reprogramming of hsa_circ_0008719 and its target miR-3615 induced by TOB1 in exosomes of gastric cancer cells: a contribution to inhibit gastric cancer progression.2025Scientific reports免费全文
  11. TOB1 inhibits the gastric cancer progression by focal adhesion pathway and ERK pathway based on transcriptional and metabolic sequencing.2024BMC cancer免费全文
  12. Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 cases.2024Cell communication and signaling : CCS免费全文
  13. GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy.2024Cellular signalling
  14. TOB1 modulates neutrophil phenotypes to influence gastric cancer progression and immunotherapy efficacy.2024Frontiers in immunology免费全文
  15. Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  16. MIEN1 on the 17q12 amplicon facilitates the malignant behaviors of gastric cancer via activating IL-6/JAK2/STAT3 pathway.2024The international journal of biochemistry & cell biology
  17. Bromodomain containing 4 inhibition combats gastric precancerous lesions via modulating macrophage polarization.2024Tissue & cell
  18. Neutrophil extracellular traps promote angiogenesis in gastric cancer.2023Cell communication and signaling : CCS免费全文
  19. Effect of NETs/COX-2 pathway on immune microenvironment and metastasis in gastric cancer.2023Frontiers in immunology免费全文
  20. Identification of lactylation related model to predict prognostic, tumor infiltrating immunocytes and response of immunotherapy in gastric cancer.2023Frontiers in immunology免费全文
  21. Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.2023Journal of cellular and molecular medicine免费全文
  22. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.2023Journal of translational medicine免费全文
  23. The Overexpression of TOB1 Induces Autophagy in Gastric Cancer Cells by Secreting Exosomes.2022Disease markers免费全文
  24. Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker.2022Frontiers in immunology免费全文
  25. Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.2022Frontiers in immunology免费全文
  26. The promoter methylation drives down-regulation mode of HIC1 in gastric cancer, its molecular characteristics and downstream functional pathways.2022Gene
  27. The Application Value of ceMDCT in the Diagnosis of Gastric Cancer Extramural Vascular Invasion and Its Influencing Factors.2022Journal of healthcare engineering免费全文
  28. The functional variant in promoter of OVCA1 was associated with the risk of gastric cancer in the northeast Chinese Han population.2022Pathology, research and practice
  29. Involvement of TOB1 on autophagy in gastric cancer AGS cells via decreasing the activation of AKT/mTOR signaling pathway.2022PeerJ免费全文
  30. Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer.2022World journal of gastroenterology免费全文
  31. The rs9953490 polymorphism of DAL-1 gene is associated with gastric cancer risk in the Han population in Northeast China.2021BMC gastroenterology免费全文
  32. Neutrophil extracellular traps promote gastric cancer metastasis by inducing epithelial‑mesenchymal transition.2021International journal of molecular medicine免费全文
  33. Anxiety and depression in recurrent gastric cancer: Their prevalence and independent risk factors analyses.2021Medicine免费全文
  34. Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.2021MedicineRCT免费全文
  35. ADAMTS12 acts as a tumor microenvironment related cancer promoter in gastric cancer.2021Scientific reports免费全文

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.5%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 2220232024: 1120242025: 222025

哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Cognitive-behavioral stress management program alleviates anxiety and depression in parents of adolescent patients with osteosarcoma.2026Psychology, health & medicine
  2. BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies.2025ACS biomaterials science & engineering
  3. MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.2025Cell death and differentiation
  4. 9-O-monoethyl succinate berberine effectively blocks the PI3K/AKT signaling pathway by targeting Wnt5a protein in inhibiting osteosarcoma growth.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Anticancer effect of crizotinib on osteosarcoma cells by targeting c-Met signaling pathway.2023Cellular and molecular biology (Noisy-le-Grand, France)
  6. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.2023Journal of orthopaedic surgery and research
  7. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.2022Bioengineered
  8. lncRNA DARS-AS1 Promoted Osteosarcoma Progression through Regulating miR-532-3p/CCR7.2022Disease markers
  9. Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.2022Frontiers in immunology
  10. LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.2022Molecular biotechnology
  11. ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.2021Cell death & disease
  12. Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR.2021Journal of cellular and molecular medicine
早期论文(2016–2020 年)12
  1. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.2020Cancer biomarkers : section A of Disease markers
  2. LncRNA-XIST promotes the oxidative stress-induced migration, invasion, and epithelial-to-mesenchymal transition of osteosarcoma cancer cells through miR-153-SNAI1 axis.2020Cell biology international
  3. Calcium-sensing receptor activating ERK1/2 and PI3K-Akt pathways to induce the proliferation of osteosarcoma cells.2020Clinical and experimental pharmacology & physiology
  4. Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.2019International journal of biological sciences
  5. The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients.2019Journal of orthopaedic surgery and research
  6. Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.2018Cancer biomarkers : section A of Disease markers
  7. Dopamine D1 receptors induce apoptosis of osteosarcoma cells via changes of MAPK pathway.2017Clinical and experimental pharmacology & physiology
  8. CpG methylation patterns are associated with gene expression variation in osteosarcoma.2017Molecular medicine reports
  9. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.2016Cancer biomarkers : section A of Disease markers
  10. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells.2016European review for medical and pharmacological sciences
  11. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α.2016Molecular and cellular biochemistry
  12. MicroRNA-145 expression in the plasma of patients with benign and malignant bone tumors and its effects on osteosarcoma cell proliferation and migration.2016Panminerva medica

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文1
  1. Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
早期论文(2016–2020 年)2
  1. [Progression of diagnosis and treatment in primary malignant small bowel tumor].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. Submucosal Tunneling Endoscopic Resection (STER) and Other Novel Applications of Submucosal Tunneling in Humans.2016Gastrointestinal endoscopy clinics of North America

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

哈尔滨有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药联合用药
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. S100A9 as a potential novel target for neuromyelitis optica spectrum disorder.2025Multiple sclerosis and related disorders
中文论文(未计入)1
  1. [Advancements and outstanding questions in neuroimmune diseases over the past decade].2024Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.6%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 0020232024: 2220242025: 002025

哈尔滨有 1 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题眼肌型重症肌无力常规免疫治疗
论文中的科室神经内科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 1 家医院列在肝包虫病下全国有 44 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.1%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 2220242025: 552025

哈尔滨有 3 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科肾内科
牵头的论文11
  1. SCPEP1+ basal cells are associated with the remodeling of oxidative stress signaling networks in idiopathic pulmonary fibrosis.2025Frontiers in immunology
  2. Orderly Regulation of Macrophages and Fibroblasts by Axl in Bleomycin-Induced Pulmonary Fibrosis in Mice.2025Journal of cellular and molecular medicine
  3. YBX1 regulation of alveolar type II epithelial cells in idiopathic pulmonary fibrosis: mechanistic insights and small-molecule drug screening.2025Journal of translational medicine
  4. Common biomarkers of idiopathic pulmonary fibrosis and systemic sclerosis based on WGCNA and machine learning.2025Scientific reports
  5. Rbms1 promotes pulmonary fibrosis by stabilising Sumo2 mRNA to facilitate Smad4-SUMOylation and fibroblast activation.2025The European respiratory journal
  6. Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.2024BMC pulmonary medicine
  7. Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis.2024Medicine
  8. Bioinformatics approach to identify the hub gene associated with COVID-19 and idiopathic pulmonary fibrosis.2023IET systems biology
  9. An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.2022BMC pulmonary medicine
  10. S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis.2022Frontiers in immunology
  11. CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopathic Pulmonary Fibrosis.2021Frontiers in immunology
早期论文(2016–2020 年)1
  1. YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF.2019Cell death and differentiation

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

哈尔滨有 1 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 2 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 0020242025: 112025

哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年没有牵头先天性膈疝的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

哈尔滨有 1 家医院列在先天性膈疝下全国有 44 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

哈尔滨有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

哈尔滨医科大学附属第二医院

Second Affiliated Hospital of Harbin Medical University

哈尔滨

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Affiliated Hospital of Harbin Medical University Harbin; second affiliated hospital of Harbin Medical University

提出更正下载数据